TABLE OF CONTENTS
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS (Page No. - 48)
4.1 GLP-1 ANALOGUES MARKET OVERVIEW
4.2 NORTH AMERICA: GLP-1 ANALOGUES MARKET SHARE, BY INDICATION AND COUNTRY (2023)
4.3 GLP-1 ANALOGUES MARKET SHARE, BY PRODUCT, 2024 VS. 2032
4.4 GLP-1 ANALOGUES MARKET SHARE, BY INDICATION, 2023
4.5 GLP-1 ANALOGUES MARKET SHARE, BY END USER, 2024 VS. 2032
4.6 GLP-1 ANALOGUES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW (Page No. - 53)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Strong R&D pipeline
5.2.1.2 Improved relative efficacy of GLP-1 drugs
5.2.1.3 High demand, expanding insurance coverage, growing sales, increasing awareness, and positive outcomes
5.2.2 RESTRAINTS
5.2.2.1 High barriers for new entrants due to duopoly
5.2.3 OPPORTUNITIES
5.2.3.1 Extended therapeutic uses
5.2.3.2 Integration of GLP-1 drugs into telehealth and digital weight management programs
5.2.4 CHALLENGES
5.2.4.1 Off-label use of GLP-1 drugs
5.2.4.2 High non-adherence to therapy after 12–24 months
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF GLP-1 ANALOGUES
5.4.2 AVERAGE SELLING PRICES OF TOP GLP-1 ANALOGUES, BY COUNTRY/REGION
5.5 TECHNOLOGY ANALYSIS
5.5.1 KEY TECHNOLOGIES
5.5.1.1 Chemical Synthesis
5.5.1.2 Recombinant DNA Technology
5.5.2 ADJACENT TECHNOLOGIES
5.5.2.1 Hydrogel Depot Technology
5.5.2.2 Technologies for oral delivery of GLP-1 analogues
5.6 PIPELINE ANALYSIS
5.7 TRADE DATA
5.8 PATENT ANALYSIS
5.8.1 METHODOLOGY
5.8.2 INNOVATION AND PATENT APPLICATIONS
5.8.3 TOP APPLICANTS
5.9 VALUE CHAIN ANALYSIS
5.10 SUPPLY CHAIN ANALYSIS
5.11 ECOSYSTEM ANALYSIS
5.11.1 GLP-1 ANALOGUES MARKET: ROLE OF RAW MATERIAL VENDORS
5.11.2 GLP-1 ANALOGUES MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE 3 PIPELINE PRODUCT COMPANIES
5.11.3 GLP-1 ANALOGUES MARKET: ROLE OF END USERS
5.11.4 GLP-1 ANALOGUES MARKET: ROLE OF REGULATORY AUTHORITIES
5.12 PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 INTENSITY OF COMPETITIVE RIVALRY
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 BUYING CRITERIA FOR GLP-1 ANALOGUES
5.14 REGULATORY LANDSCAPE
5.14.1 REGULATORY SCENARIO
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14.2.1 North America
5.14.2.2 Europe
5.14.2.3 Asia Pacific
5.14.2.4 Rest of the World
5.15 KEY CONFERENCES & EVENTS, 2024–2025
5.16 CASE STUDIES
5.16.1 STUDY OF TIRZEPATIDE AS A CASE IN GLP-1 DRUGS MARKET
5.16.2 OZEMPIC OFF-LABEL USE
5.17 INVESTMENT AND FUNDING SCENARIO
6 GLP-1 ANALOGUES MARKET, BY PRODUCT (Page No. - 91)
6.1 INTRODUCTIONS
6.2 OZEMPIC
6.2.1 RISING ADOPTION TO SUPPORT MARKET GROWTH
6.3 TRULICITY
6.3.1 COMPETITOR REVENUE GROWTH TO AFFECT GROWTH
6.4 MOUNJARO
6.4.1 EXPONENTIAL GROWTH ANTICIPATED DUE TO HIGH ADOPTION IN NORTH AMERICA
6.5 WEGOVY
6.5.1 INCREASING USE FOR WEIGHT MANAGEMENT TO SUPPORT GROWTH
6.6 RYBELSUS
6.6.1 CONVENIENCE OF ORAL ADMINISTRATION TO DRIVE MARKET
6.7 SAXENDA
6.7.1 DEVELOPMENT OF GENERIC VERSIONS TO SLOW GROWTH
6.8 VICTOZA
6.8.1 ADOPTION OF ORAL GLP-1S TO RESTRAIN MARKET GROWTH
6.9 XULTOPHY
6.9.1 REGULATORY APPROVALS TO SUPPORT MARKET GROWTH
6.1 SOLIQUA
6.10.1 COMPETITOR GLP-1 PRODUCTS THREAT TO GROWTH
6.11 ZEPBOUND
6.11.1 STRONG REVENUE GROWTH TO ENSURE CONTINUED PRESENCE
6.12 BYDUREON
6.12.1 COMPETITOR PRODUCTS TO AFFECT MARKET GROWTH
6.13 OTHER PRODUCTS
7 GLP-1 ANALOGUES MARKET, BY FORMAT (Page No. - 118)
7.1 INTRODUCTIONS
7.2 SINGLE DOSE
7.2.1 HIGH ADOPTION DUE TO EASE OF ADMINISTRATION TO SUPPORT GROWTH
7.3 MULTI-DOSE
7.3.1 LOW COST TO ATTRACT LARGER ADOPTION
7.4 TABLETS
7.4.1 DEVELOPMENT OF HIGH-POTENCY GLP-1S TO SUPPORT MARKET GROWTH
8 GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 128)
8.1 INTRODUCTION
8.2 SUBCUTANEOUS ADMINISTRATION
8.2.1 PEN INJECTORS
8.2.1.1 Ease of monitoring to support adoption
8.2.2 AUTOINJECTORS
8.2.2.1 Advantages offered over pen injectors to support adoption
8.3 ORAL ADMINISTRATION
8.3.1 ELIMINATION OF NEEDLE PHOBIA AND EASE OF USE TO DRIVE COMPLIANCE
9 GLP-1 ANALOGUES MARKET, BY INDICATION (Page No. - 142)
9.1 INTRODUCTION
9.2 DIABETES
9.2.1 HIGH EFFICACY TO SUPPORT MARKET GROWTH
9.3 OBESITY
9.3.1 INCREASING DEMAND AND PIPELINE FOCUS ON ANTI-OBESITY GLP-1S TO DRIVE MARKET
9.4 OTHER INDICATIONS
10 GLP-1 ANALOGUES MARKET, BY END USER (Page No. - 152)
10.1 INTRODUCTIONS
10.2 HOME CARE SETTINGS
10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
10.3 LONG-TERM CARE FACILITIES
10.3.1 GROWING GERIATRIC POPULATION AND RISING CHRONIC DISEASE INCIDENCE TO DRIVE MARKET
10.4 HOSPITALS & SPECIALTY CLINICS
10.4.1 ADOPTION OF GLP-1 FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH
11 GLP-1 ANALOGUES MARKET, BY REGION (Page No. - 163)
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 Strategic developments by major players and R&D activities to drive market
11.2.3 CANADA
11.2.3.1 Strong research infrastructure and availability of funding to support market growth
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 Improving accessibility to support market growth in Germany
11.3.3 UK
11.3.3.1 Increasing research to evaluate efficacy and potential of GLP-1 analogues to support market growth
11.3.4 FRANCE
11.3.4.1 Growing awareness to propel market growth
11.3.5 ITALY
11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market
11.3.6 SPAIN
11.3.6.1 Favorable initiatives for research to drive market
11.3.7 NETHERLANDS
11.3.7.1 Growing awareness and strong focus on pharmaceutical R&D to support market growth
11.3.8 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
11.4.2 CHINA
11.4.2.1 Expansion of major biotechnology and pharmaceutical companies in China to drive market
11.4.3 JAPAN
11.4.3.1 Growing availability of prominent GLP-1 drugs to drive market
11.4.4 INDIA
11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth
11.4.5 AUSTRALIA
11.4.5.1 Access to GLP-1 drugs and government support to drive market
11.4.6 SOUTH KOREA
11.4.6.1 Collaborations in obesity drugs to propel market growth
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: RECESSION IMPACT
11.5.2 BRAZIL
11.5.2.1 Brazil to hold largest market share in Latin America
11.5.3 MEXICO
11.5.3.1 Growing diabetes and obesity cases to support market growth
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 MIDDLE EAST: RECESSION IMPACT
11.6.2 GCC COUNTRIES
11.6.2.1 Saudi Arabia
11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth
11.6.2.2 UAE
11.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to support market growth
11.6.2.3 Rest of GCC countries
11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
11.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH
11.7.2 AFRICA: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE (Page No. - 249)
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 ANALOGUES MARKET
12.3 REVENUE ANALYSIS
12.4 MARKET SHARE ANALYSIS
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.6 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023
12.6.1 STARS
12.6.2 EMERGING LEADERS
12.6.3 PERVASIVE PLAYERS
12.6.4 PARTICIPANTS
12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.6.5.1 Company Footprint
12.6.5.2 Format footprint
12.6.5.3 Route of administration footprint
12.6.5.4 Indication footprint
12.6.5.5 Region footprint
12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.7.1 PROGRESSIVE COMPANIES
12.7.2 RESPONSIVE COMPANIES
12.7.3 DYNAMIC COMPANIES
12.7.4 STARTING BLOCKS
12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.8 VALUATION & FINANCIAL METRICS
12.8.1 FINANCIAL METRICS
12.8.2 COMPANY VALUATION
12.9 BRAND/PRODUCT COMPARISON
12.1 COMPETITIVE SCENARIO
12.10.1 PRODUCT APPROVALS
12.10.2 DEALS
12.10.3 EXPANSIONS
12.10.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES (Page No. - 272)
13.1 INTRODUCTION
13.2 KEY PLAYERS
13.2.1 NOVO NORDISK A/S
13.2.1.1 Business overview
13.2.1.2 Products offered
13.2.1.3 Recent developments
13.2.1.3.1 Product approvals
13.2.1.3.2 Expansions
13.2.1.3.3 Other developments
13.2.1.4 MnM view
13.2.1.4.1 Right to win
13.2.1.4.2 Strategic choices
13.2.1.4.3 Weaknesses & competitive threats
13.2.2 ELI LILLY AND COMPANY
13.2.2.1 Business overview
13.2.2.2 Products offered
13.2.2.3 Recent developments
13.2.2.3.1 Product approvals
13.2.2.3.2 Deals
13.2.2.3.3 Expansions
13.2.2.4 MnM view
13.2.2.4.1 Right to win
13.2.2.4.2 Strategic choices
13.2.2.4.3 Weaknesses & competitive threats
13.2.3 SANOFI
13.2.3.1 Business overview
13.2.3.2 Products offered
13.2.3.3 MnM view
13.2.3.3.1 Key strengths
13.2.3.3.2 Strategic choices
13.2.3.3.3 Weaknesses & competitive threats
13.2.4 ASTRAZENECA
13.2.4.1 Business overview
13.2.4.2 Products offered
13.2.4.3 Recent developments
13.2.4.3.1 Product approvals
13.2.4.4 MnM view
13.2.4.4.1 Right to win
13.2.4.4.2 Strategic choices
13.2.4.4.3 Weaknesses & competitive threats
13.2.5 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
13.2.5.1 Business overview
13.2.5.2 Products offered
13.2.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.2.6.1 Business overview
13.2.6.2 Products in pipeline
13.2.6.3 Recent developments
13.2.6.3.1 Deals
13.2.6.3.2 Other developments
13.2.7 INNOVENT
13.2.7.1 Business overview
13.2.7.2 Products in pipeline
13.2.7.3 Recent developments
13.2.7.3.1 Other developments
13.2.8 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
13.2.8.1 Business overview
13.2.8.2 Products in pipeline
13.2.9 SCIWIND BIOSCIENCES CO., LTD.
13.2.9.1 Business overview
13.2.9.2 Products in pipeline
13.2.9.3 Recent developments
13.2.9.3.1 Deals
13.2.9.3.2 Other developments
13.2.10 ZEALAND PHARMA A/S
13.2.10.1 Business overview
13.2.10.2 Products in pipeline
13.2.10.3 Recent developments
13.2.10.3.1 Deals
13.2.10.3.2 Other developments
13.2.11 BEIJING DONGFANG BAITAI BIOTECHNOLOGY CO., LTD (EASTERN BIOTECH)
13.2.11.1 Business overview
13.2.11.2 Products in pipeline
13.3 OTHER PLAYERS
13.3.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
13.3.2 VTV THERAPEUTICS
13.3.3 TERNS PHARMACEUTICALS, INC.
13.3.4 ALTIMMUNE
13.3.5 SCOHIA PHARMA, INC.
13.3.6 STRUCTURE THERAPEUTICS
13.3.7 NEUROBO PHARMACEUTICALS, INC.
13.3.8 I2O THERAPEUTICS, INC.
13.3.9 AMGEN INC.
13.3.10 PFIZER INC.
13.3.11 MERCK & CO., INC.
13.3.12 HANMI PHARM CO., LTD.
13.3.13 VIKING THERAPEUTICS
13.3.14 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
14 APPENDIX (Page No. - 308)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
LIST OF TABLES (405 TABLES)
TABLE 1 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)
TABLE 2 GLP-1 ANALOGUES MARKET: IMPACT ANALYSIS
TABLE 3 AVERAGE SELLING PRICE RANGE OF TOP GLP-1 ANALOGUES (2023–2024)
TABLE 4 GLP-1 ANALOGUES IN CLINICAL PIPELINE (AS OF MAY 2024)
TABLE 5 TOP 20 PATENT OWNERS IN GLP-1 ANALOGUES MARKET, 2014–2024
TABLE 6 INDICATIVE LIST OF PATENTS IN GLP-1 ANALOGUES MARKET, 2022–2024
TABLE 7 GLP-1 ANALOGUES MARKET: ROLE OF RAW MATERIAL VENDORS
TABLE 8 GLP-1 ANALOGUES MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE 3 PIPELINE PRODUCT COMPANIES
TABLE 9 GLP-1 ANALOGUES MARKET: ROLE OF END USERS
TABLE 10 GLP-1 ANALOGUES MARKET: ROLE OF REGULATORY AUTHORITIES
TABLE 11 GLP-1 ANALOGUES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 12 BUYING CRITERIA FOR GLP-1 ANALOGUES, BY END USER
TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 GLP-1 ANALOGUES MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2024–2025
TABLE 18 GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 19 GLP-1 ANALOGUES MARKET FOR ANTI-OBESITY PRODUCTS (MILLION UNITS)
TABLE 20 OZEMPIC MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 21 NORTH AMERICA: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 22 EUROPE: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 23 ASIA PACIFIC: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 24 LATIN AMERICA: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 25 MIDDLE EAST: OZEMPIC MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 26 GCC COUNTRIES: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 27 TRULICITY MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 28 NORTH AMERICA: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 29 EUROPE: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 30 ASIA PACIFIC: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 31 LATIN AMERICA: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 32 MIDDLE EAST: TRULICITY MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 33 GCC COUNTRIES: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 34 MOUNJARO MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 35 NORTH AMERICA: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 36 EUROPE: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 37 ASIA PACIFIC: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 38 LATIN AMERICA: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 39 MIDDLE EAST: MOUNJARO MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 40 GCC COUNTRIES: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 41 WEGOVY MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 42 NORTH AMERICA: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 43 EUROPE: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 44 ASIA PACIFIC: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 45 LATIN AMERICA: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 46 MIDDLE EAST: WEGOVY MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 47 GCC COUNTRIES: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 48 RYBELSUS MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 49 NORTH AMERICA: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 50 EUROPE: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 51 ASIA PACIFIC: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 52 LATIN AMERICA: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 53 MIDDLE EAST: RYBELSUS MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 54 GCC COUNTRIES: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 55 SAXENDA MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 56 NORTH AMERICA: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 57 EUROPE: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 58 ASIA PACIFIC: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 59 LATIN AMERICA: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 60 MIDDLE EAST: SAXENDA MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 61 GCC COUNTRIES: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 62 VICTOZA MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 63 NORTH AMERICA: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 64 EUROPE: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 65 ASIA PACIFIC: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 66 LATIN AMERICA: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 67 MIDDLE EAST: VICTOZA MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 68 GCC COUNTRIES: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 69 XULTOPHY MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 70 SOLIQUA MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 71 ZEPBOUND MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 72 NORTH AMERICA: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 73 EUROPE: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 74 ASIA PACIFIC: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 75 LATIN AMERICA: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 76 MIDDLE EAST: ZEPBOUND MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 77 GCC COUNTRIES: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 78 BYDUREON MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 79 OTHER PRODUCTS MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 80 GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 81 SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 82 NORTH AMERICA: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 83 EUROPE: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 84 ASIA PACIFIC: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 85 LATIN AMERICA: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 86 MIDDLE EAST: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 87 GCC COUNTRIES: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 88 MULTI-DOSE GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 89 NORTH AMERICA: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 90 EUROPE: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 91 ASIA PACIFIC: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 92 LATIN AMERICA: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 93 MIDDLE EAST: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 94 GCC COUNTRIES: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 95 GLP-1 ANALOGUE TABLETS MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 96 NORTH AMERICA: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 97 EUROPE: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 98 ASIA PACIFIC: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 99 LATIN AMERICA: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 100 MIDDLE EAST: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 101 GCC COUNTRIES: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 102 GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 103 SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 104 SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 105 NORTH AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
TABLE 106 EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 107 ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 108 LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 109 MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 110 GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 111 GLP-1 ANALOGUE PEN INJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 112 NORTH AMERICA: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 113 EUROPE: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 114 ASIA PACIFIC: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 115 LATIN AMERICA: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 116 MIDDLE EAST: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 117 GCC COUNTRIES: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 118 GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 119 NORTH AMERICA: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 120 EUROPE: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 121 ASIA PACIFIC: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 122 LATIN AMERICA: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 123 MIDDLE EAST: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 124 GCC COUNTRIES: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 125 ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 126 NORTH AMERICA: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 127 EUROPE: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 128 ASIA PACIFIC: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 129 LATIN AMERICA: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 130 MIDDLE EAST: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD MILLION)
TABLE 131 GCC COUNTRIES: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 132 GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 133 GLP-1 ANALOGUES MARKET FOR DIABETES, BY REGION, 2022–2032 (USD BILLION)
TABLE 134 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 135 EUROPE: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 136 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 137 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 138 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR DIABETES, BY REGION, 2022–2032 (USD BILLION)
TABLE 139 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 140 GLP-1 ANALOGUES MARKET FOR OBESITY, BY REGION, 2022–2032 (USD BILLION)
TABLE 141 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 142 EUROPE: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 143 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 144 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 145 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR OBESITY, BY REGION, 2022–2032 (USD BILLION)
TABLE 146 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 147 GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2032 (USD BILLION)
TABLE 148 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 149 EUROPE: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 150 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 151 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 152 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2032 (USD BILLION)
TABLE 153 GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 154 GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2032 (USD BILLION)
TABLE 155 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 156 EUROPE: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 157 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 158 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 159 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2032 (USD BILLION)
TABLE 160 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 161 GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2032 (USD BILLION)
TABLE 162 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 163 EUROPE: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 164 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 165 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 166 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2032 (USD BILLION)
TABLE 167 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 168 GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022–2032 (USD BILLION)
TABLE 169 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 170 EUROPE: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 171 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 172 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 173 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022–2032 (USD BILLION)
TABLE 174 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 175 GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 176 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 177 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 178 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 179 NORTH AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 180 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 181 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 182 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 183 US: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 184 US: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 185 US: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 186 US: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 187 US: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 188 US: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 189 CANADA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 190 CANADA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 191 CANADA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 192 CANADA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 193 CANADA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 194 CANADA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 195 EUROPE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 196 EUROPE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 197 EUROPE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 198 EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 199 EUROPE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 200 EUROPE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 201 EUROPE: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 202 GERMANY: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 203 GERMANY: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 204 GERMANY: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 205 GERMANY: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 206 GERMANY: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 207 GERMANY: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 208 UK: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 209 UK: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 210 UK: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 211 UK: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 212 UK: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 213 UK: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 214 FRANCE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 215 FRANCE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 216 FRANCE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 217 FRANCE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 218 FRANCE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 219 FRANCE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 220 ITALY: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 221 ITALY: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 222 ITALY: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 223 ITALY: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 224 ITALY: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 225 ITALY: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 226 SPAIN: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 227 SPAIN: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 228 SPAIN: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 229 SPAIN: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 230 SPAIN: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 231 SPAIN: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 232 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 233 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 234 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 235 NETHERLANDS: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 236 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 237 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 238 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 239 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 240 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 241 REST OF EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 242 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 243 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 244 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 245 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 246 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 247 ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 248 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 249 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 250 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 251 CHINA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 252 CHINA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 253 CHINA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 254 CHINA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 255 CHINA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 256 CHINA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 257 JAPAN: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 258 JAPAN: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 259 JAPAN: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 260 JAPAN: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 261 JAPAN: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 262 JAPAN: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 263 INDIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 264 INDIA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 265 INDIA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 266 INDIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 267 INDIA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 268 INDIA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 269 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 270 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 271 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 272 AUSTRALIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 273 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 274 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 275 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 276 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 277 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 278 SOUTH KOREA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 279 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 280 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 281 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 282 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 283 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 284 REST OF ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 285 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 286 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 287 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 288 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 289 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 290 LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 291 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 292 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 293 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 294 BRAZIL: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 295 BRAZIL: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 296 BRAZIL: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 297 BRAZIL: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 298 BRAZIL: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 299 BRAZIL: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 300 MEXICO: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 301 MEXICO: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 302 MEXICO: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 303 MEXICO: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 304 MEXICO: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 305 MEXICO: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 306 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 307 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 308 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 309 REST OF LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 310 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 311 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 312 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 313 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 314 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 315 MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 316 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 317 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 318 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
TABLE 319 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 320 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 321 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 322 GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 323 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 324 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 325 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
TABLE 326 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 327 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 328 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 329 SAUDI ARABIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 330 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 331 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 332 UAE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 333 UAE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 334 UAE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 335 UAE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 336 UAE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 337 UAE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 338 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 339 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 340 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 341 REST OF GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 342 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 343 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 344 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 345 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 346 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 347 REST OF MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 348 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 349 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 350 AFRICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
TABLE 351 AFRICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
TABLE 352 AFRICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
TABLE 353 AFRICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
TABLE 354 AFRICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
TABLE 355 AFRICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
TABLE 356 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
TABLE 357 GLP-1 ANALOGUES MARKET: DEGREE OF COMPETITION
TABLE 358 GLP-1 ANALOGUES MARKET: FORMAT FOOTPRINT
TABLE 359 GLP-1 ANALOGUES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
TABLE 360 GLP-1 ANALOGUES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
TABLE 361 GLP-1 ANALOGUES MARKET: INDICATION FOOTPRINT (KEY PLAYERS)
TABLE 362 GLP-1 ANALOGUES MARKET: INDICATION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
TABLE 363 GLP-1 ANALOGUES MARKET: REGION FOOTPRINT (KEY PLAYERS)
TABLE 364 GLP-1 ANALOGUES MARKET: DETAILED LIST OF KEY START-UPS/SMES
TABLE 365 GLP-1 ANALOGUES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
TABLE 366 GLP-1 ANALOGUES MARKET: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 367 GLP-1 ANALOGUES MARKET: DEALS, JANUARY 2021–MAY 2024
TABLE 368 GLP-1 ANALOGUES MARKET: EXPANSIONS, JANUARY 2021–MAY 2024
TABLE 369 GLP-1 ANALOGUES MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
TABLE 370 NOVO NORDISK A/S: COMPANY OVERVIEW
TABLE 371 NOVO NORDISK A/S: PRODUCTS OFFERED
TABLE 372 NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024
TABLE 373 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2021–APRIL 2024
TABLE 374 NOVO NORDISK A/S: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
TABLE 375 ELI LILLY AND COMPANY: COMPANY OVERVIEW
TABLE 376 ELI LILLY AND COMPANY: PRODUCTS OFFERED
TABLE 377 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024
TABLE 378 ELI LILLY AND COMPANY: DEALS, JANUARY 2021–APRIL 2024
TABLE 379 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2021–APRIL 2024
TABLE 380 SANOFI: COMPANY OVERVIEW
TABLE 381 SANOFI: PRODUCTS OFFERED
TABLE 382 ASTRAZENECA: COMPANY OVERVIEW
TABLE 383 ASTRAZENECA: PRODUCTS OFFERED
TABLE 384 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024
TABLE 385 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: COMPANY OVERVIEW
TABLE 386 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: PRODUCTS OFFERED
TABLE 387 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
TABLE 388 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS IN PIPELINE
TABLE 389 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2021–APRIL 2024
TABLE 390 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
TABLE 391 INNOVENT: COMPANY OVERVIEW
TABLE 392 INNOVENT: PRODUCTS IN PIPELINE
TABLE 393 INNOVENT: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
TABLE 394 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.: COMPANY OVERVIEW
TABLE 395 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.: PRODUCTS IN PIPELINE
TABLE 396 SCIWIND BIOSCIENCES CO., LTD.: COMPANY OVERVIEW
TABLE 397 SCIWIND BIOSCIENCES CO., LTD.: PRODUCTS IN PIPELINE
TABLE 398 SCIWIND BIOSCIENCES CO., LTD.: DEALS, JANUARY 2021–APRIL 2024
TABLE 399 SCIWIND BIOSCIENCES CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
TABLE 400 ZEALAND PHARMA A/S: COMPANY OVERVIEW
TABLE 401 ZEALAND PHARMA A/S: PRODUCTS IN PIPELINE
TABLE 402 ZEALAND PHARMA A/S: DEALS, JANUARY 2021–APRIL 2024
TABLE 403 ZEALAND PHARMA A/S: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
TABLE 404 BEIJING DONGFANG BAITAI BIOTECHNOLOGY: COMPANY OVERVIEW
TABLE 405 BEIJING DONGFANG BAITAI BIOTECHNOLOGY: PRODUCTS IN PIPELINE
LIST OF FIGURES (59 FIGURES)
FIGURE 1 GLP-1 ANALOGUES MARKET SEGMENTATION
FIGURE 2 GLP-1 ANALOGUES MARKET: REGIONAL SEGMENTATION
FIGURE 3 RESEARCH DESIGN
FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
FIGURE 8 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 9 CAGR PROJECTIONS: GLP-1 ANALOGUES MARKET, 2024–2032
FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN GLP-1 ANALOGUES MARKET
FIGURE 11 DATA TRIANGULATION METHODOLOGY
FIGURE 12 GLP-1 ANALOGUES MARKET, BY PRODUCT, 2024 VS. 2032 (USD BILLION)
FIGURE 13 GLP-1 ANALOGUES MARKET SHARE, BY FORMAT, 2024 VS. 2032 (USD BILLION)
FIGURE 14 GLP-1 ANALOGUES MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2024 VS. 2032 (USD BILLION)
FIGURE 15 GLP-1 ANALOGUES MARKET SHARE, BY INDICATION, 2024 VS. 2032 (USD BILLION)
FIGURE 16 GLP-1 ANALOGUES MARKET, BY END USER, 2024−2032 (USD BILLION)
FIGURE 17 GLP-1 ANALOGUES MARKET: GEOGRAPHICAL SNAPSHOT
FIGURE 18 IMPROVED EFFICACY OF GLP-1 DRUGS TO DRIVE MARKET GROWTH
FIGURE 19 DIABETES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
FIGURE 20 OZEMPIC TO DOMINATE MARKET IN 2032
FIGURE 21 DIABETES INDICATIONS TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
FIGURE 22 HOME CARE SETTINGS TO DOMINATE THE MARKET IN 2032
FIGURE 23 US TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 24 GLP-1 ANALOGUES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 25 US: PREVALENCE OF INDICATIONS THAT MAY RESPOND TO GLP-1 DRUGS (AS OF JANUARY 2024)
FIGURE 26 REVENUE SHIFT IN GLP-1 ANALOGUES MARKET
FIGURE 27 AVERAGE SELLING PRICE TREND, BY PRODUCT
FIGURE 28 PRODUCT PRICING, BY COUNTRY (2023–2024)
FIGURE 29 ADDITIONAL LAUNCHES OF GLP-1 DRUGS, 2025–2032
FIGURE 30 PHASE 3 PIPELINE, BY INDICATION
FIGURE 31 TOTAL NUMBER OF PATENTS GRANTED, 2014–2024
FIGURE 32 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2024
FIGURE 33 VALUE CHAIN ANALYSIS: PRODUCT DEVELOPMENT AND MANUFACTURING PHASE CONTRIBUTES MAXIMUM VALUE
FIGURE 34 GLP-1 ANALOGUES MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 35 GLP-1 ANALOGUES MARKET: ECOSYSTEM ANALYSIS
FIGURE 36 GLP-1 ANALOGUES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 37 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GLP-1 ANALOGUES, HOSPITALS
FIGURE 38 KEY BUYING CRITERIA FOR END USERS
FIGURE 39 NORTH AMERICA GLP-1 ANALOGUES MARKET SNAPSHOT
FIGURE 40 EUROPE: GLP-1 ANALOGUES MARKET SNAPSHOT
FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN GLP-1 ANALOGUES MARKET, 2021–2023
FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GLP-1 ANALOGUES MARKET, 2023
FIGURE 43 GLP-1 ANALOGUES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 44 GLP-1 ANALOGUES MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2023
FIGURE 45 GLP-1 ANALOGUES MARKET: COMPANY FOOTPRINT (KEY PLAYERS)
FIGURE 46 GLP-1 ANALOGUES MARKET: COMPANY FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
FIGURE 47 GLP-1 ANALOGUES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 48 EV/EBITDA OF KEY VENDORS
FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 50 GLP-1 ANALOGUES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS (ANTIDIABETIC GLP-1 ANALOGUES)
FIGURE 51 GLP-1 ANALOGUES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS (ANTI-OBESITY GLP-1 ANALOGUES)
FIGURE 52 NOVO NORDISK A/S: COMPANY SNAPSHOT
FIGURE 53 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
FIGURE 54 SANOFI: COMPANY SNAPSHOT
FIGURE 55 ASTRAZENECA: COMPANY SNAPSHOT
FIGURE 56 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: COMPANY SNAPSHOT
FIGURE 57 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
FIGURE 58 INNOVENT: COMPANY SNAPSHOT
FIGURE 59 ZEALAND PHARMA A/S: COMPANY SNAPSHOT
Growth opportunities and latent adjacency in GLP-1 Analogues Market